BringCom’s Post

++ 𝐄𝐱𝐩𝐚𝐧𝐝𝐞𝐝 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡-𝐂𝐄𝐏𝐈 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐭𝐨 𝐬𝐭𝐫𝐞𝐧𝐠𝐭𝐡𝐞𝐧 𝐀𝐟𝐫𝐢𝐜𝐚’𝐬 𝐦𝐑𝐍𝐀 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 +++ Today we announced an expanded partnership with CEPI (Coalition for Epidemic Preparedness Innovations) to broaden the scope of our manufacturing facility in Africa. With this we also want to support the entire spectrum – from local research and clinical trials to commercial production.  🌍 𝐂𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐧𝐠 𝐭𝐨 𝐞𝐪𝐮𝐢𝐭𝐚𝐛𝐥𝐞 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐧𝐨𝐯𝐞𝐥 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬: BioNTech and CEPI commit to enabling equitable access, including affordable pricing to select vaccines produced at BioNTech’s facility in Kigali, with priority access to African countries. 🛡 𝐖𝐨𝐫𝐤𝐢𝐧𝐠 𝐣𝐨𝐢𝐧𝐭𝐥𝐲 𝐨𝐧 𝐀𝐟𝐫𝐢𝐜𝐚’𝐬 𝐩𝐚𝐧𝐝𝐞𝐦𝐢𝐜 𝐩𝐫𝐞𝐩𝐚𝐫𝐞𝐝𝐧𝐞𝐬𝐬: In the event of a disease outbreak, BioNTech would dedicate up to half of the facility’s manufacturing capacity to produce emergency response mRNA vaccines, subject to regulatory authorization.  🥼 𝐒𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐦𝐑𝐍𝐀 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 𝐢𝐧 𝐀𝐟𝐫𝐢𝐜𝐚: BioNTech will dedicate manufacturing capacities to third party projects aimed at enabling R&D activities for novel mRNA-based vaccine candidates against pathogens with epidemic or pandemic potential. We are thankful for the trust put in us by various partners and collaborators. Our joint efforts are aimed at supporting the African Union’s and Africa CDC's goal of producing 60 percent of total vaccine doses required on the continent by 2040. 𝑳𝒊𝒏𝒌 𝒕𝒐 𝒑𝒓𝒆𝒔𝒔 𝒓𝒆𝒍𝒆𝒂𝒔𝒆 𝒂𝒏𝒅 𝒇𝒐𝒓𝒘𝒂𝒓𝒅-𝒍𝒐𝒐𝒌𝒊𝒏𝒈 𝒔𝒕𝒂𝒕𝒆𝒎𝒆𝒏𝒕𝒔: https://lnkd.in/evyfhEYs  

#Lancet #MalariaVaccine #2Candidates #RTS,S/AS01 #R21Matrix-M A key finding in 2021 was the #successful demonstration of programmatic #feasibility, #effectiveness, and #safety of #RTS,S/AS01 in very large #pilot implementations in three African countries. Demand for #malaria #vaccines is unprecedented, with #18countries already #approved for #Gavi, the Vaccine Alliance support for vaccine introduction in 2024. However, #supply of RTS,S/AS01 is severely #constrained, with only 18 million doses available between 2023 and 2025, and the annual demand is anticipated to be around 80–100 million doses. #Inventors at the University of Oxford (#Oxford, UK), in partnership with the #SerumInstitute of India (Pune, India), have now #developed a second, #circumsporozoite-based #vaccine similar in construct to RTS,S/AS01, known as #R21Matrix-M. Like RTS,S/AS01, the R21/Matrix-M vaccine targets the circumsporozoite antigen. The #SerumInstitute of #India has a track record of #supplying other WHO-recommended vaccines at very #largescale, at relatively #lowcost, and of meeting WHO's prequalification standards on vaccine quality, safety, and efficacy. https://lnkd.in/gUX9aEYw

Gavi has gone from providing support for vaccines against six infectious diseases in 2000 to 19 in 2022! But how do we decide which vaccines to invest in? From consulting experts from around the world to decisions by the Gavi Board, learn about the process: The vaccine landscape is becoming increasingly complex. The latest Vaccine Investment Strategy has been updated to reflect the challenges posed by antimicrobial resistance and #climatechange: The Vaccine Investment Strategy enables Gavi to maximise the number of lives it helps save and the number of people whose health it improves, and facilitates long‑term planning for partners, donors, manufacturers and Gavi‑implementing countries.

A New TB Vaccine: At last, a century later, a promising vaccine against TB is on the horizon. Developed by consortia led by Spanish Institute after 30 years, it is undergoing trials. In India, which continues to hold the dubious distinction of having the world’s largest number of cases, the trials will be doing jointly by Hyderabad based, Bharat Biotech and the Spanish Biofabri. BCG, is an attenuated vaccine while the new one is derived from human sources. The new vaccine is targeted at adults and adolescents protection. Read for a detailed story on the hope the vaccine has generated so far in my article in Siasat.com

Global Vaccine Force Gets Boost: Serum Institute of India Pvt. Ltd. Institute Joins CEPI (Coalition for Epidemic Preparedness Innovations) Network The world's largest vaccine manufacturer, Serum Institute of India (SII), has joined forces with the Coalition for Epidemic Preparedness Innovations (CEPI). This new #partnership aims to strengthen #vaccine production capabilities in the Global South, ensuring quicker and more equitable access to life-saving vaccines during #pandemics. CEPI, a global partnership focused on accelerating vaccine development, will invest $30 million in SII to bolster its ability to quickly produce and supply affordable investigational vaccines in the event of an epidemic or pandemic. This builds on SII's impressive track record of responding swiftly to #infectious diseases, like its crucial role in manufacturing COVID-19 vaccines. "This collaboration will enable CEPI-backed vaccine developers to swiftly transfer their technology to SII within days or weeks of an outbreak," noted the joint statement. This streamlined process will allow for rapid production and distribution of vital vaccines, particularly in developing countries often hit hardest by pandemics. SII's CEO, Adar Poonawalla, emphasized the company's commitment to leveraging its "well-established manufacturing and rapid response capabilities" to improve global pandemic preparedness. "This partnership will enable us to respond more rapidly to public health disease outbreaks, particularly in Global South countries," he added. With SII's production capacity of 4 billion doses annually and CEPI's expertise in accelerating vaccine development, this partnership stands to significantly enhance the world's ability to combat future pandemics. The collaboration promises faster vaccine production, broader accessibility, and ultimately, greater protection for all, especially in vulnerable regions.

📣 We’ve today announced new research to expand access to the world’s first Chikungunya vaccine in outbreak-affected countries. The clinical trials, funded by CEPI and the European Union Horizon Europe programme, will help generate additional data to potentially support licensure of Valneva's #Chikungunya vaccine in endemic countries and at-risk populations, such as children and pregnant women. Several thousand participants are set to take part in the planned trials, due to start in 2025. Some trials are planned to be conducted in Brazil, which is currently facing a significant Chikungunya outbreak with over 340,000 cases reported so far this year. Through the CEPI-EU partnership, Valneva are already working with Brazil’s Instituto Butantan who are committed to developing and producing the Chikungunya vaccine at an affordable price for distribution in Latin American countries. CEPI-EU funding will also support technology transfer of the vaccine drug product to an additional vaccine manufacturer to accelerate and expand access to IXCHIQ® in low- and middle-income countries in Asia that are vulnerable to chikungunya outbreaks. More ⬇

📣 We are expanding our partnership with BioNTech SE to enhance mRNA vaccine R&D, clinical and commercial-scale manufacturing capabilities at BioNTech’s facility in Kigali, Rwanda. CEPI’s investment of up to US$145 million will help to establish sustainable and resilient end-to-end regional infrastructure and enable faster and more equitable responses to disease outbreaks with epidemic or pandemic potential in Africa. Expanding and diversifying the global footprint of vaccine manufacturing is critical to enabling equitable access to life-saving vaccines and delivering the #100DaysMission.  Under the terms of the agreement, BioNTech intends to provide affordable access to vaccines manufactured at the Kigali facility, such as vaccines against malaria, mpox and tuberculosis, to low and middle-income countries, with priority supply to African countries, if successfully developed and authorized. CEPI and BioNTech will work jointly to respond to outbreaks in Africa, and in the event of a disease outbreak - or a potential disease outbreak - BioNTech would dedicate up to half of the facility’s manufacturing capacity to produce emergency response mRNA vaccines, subject to regulatory authorization. Designed to manufacture a range of mRNA-based vaccines, BioNTech’s Kigali manufacturing facility could become the first commercial mRNA facility in Africa, intended to support the African Union’s and Africa CDC’s goal of producing 60 percent of total vaccine doses required on the continent by 2040.  https://lnkd.in/e8zdNUgW

🗞️ New Publication Alert! 🗞️ Teamit's Fabio Riefolo, PhD has co-authored a new study as part of the VAC4EU - Vaccine Monitoring Collaboration for Europe project "What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European “Covid Vaccine Monitor” Active Surveillance Study". 🔍Published in #DrugSafety, this important research investigates the safety profile of #COVID-19 vaccines in immunocompromised individuals, a group for which this safety data had not yet been extensively evaluated. 📊The encouraging findings suggest a favourable safety profile of first and booster doses of #COVID-19 vaccines in #immunocompromised individuals. Teamit is incredibly proud to contribute to pioneering #pharmacoepidemiology💊 projects like VAC4EU. Our expertise in scientific management, regulatory science, and real-world evidence👥 plays a crucial role in advancing these important studies. ⬇️Read the full paper below⬇️ https://lnkd.in/d-z8dcbF Eva Molero Romen Gianmarco Di Mauro, PhD, Dana D., Elena Palà Vila, Anna Brutau Abia, Ph.D., Irene Pazos,

🌍 𝗧𝗵𝗲 𝗔𝗳𝗿𝗶𝗰𝗮𝗻 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲 𝗼𝗳 𝟮𝟬𝟯𝟬 - 𝗬𝗼𝘂𝗿 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗠𝗮𝗸𝗲 𝗮 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲! 🌱 Today, I would like to shed light about the African Vaccine Manufacturing Initiative of 2030, launched by Africa CDC (Centers for Disease Control and Prevention). 𝑺𝒐, 𝒘𝒉𝒂𝒕 𝒆𝒙𝒂𝒄𝒕𝒍𝒚 𝒊𝒔 𝒕𝒉𝒊𝒔 𝒊𝒏𝒊𝒕𝒊𝒂𝒕𝒊𝒗𝒆 𝒂𝒃𝒐𝒖𝒕? The goal of the African Vaccine Manufacturing Initiative (AVMI) is to establish a sustainable vaccine manufacturing industry in Africa. With support from The Global Vaccine Alliance (GAVI) Board, AVMI aims to make up to US$ 1 billion available to support vaccine manufacturing across the continent. This is an incredible opportunity for Africa to become self-reliant in vaccine production and ensure access to critical vaccines, even in times of health emergencies. The AVMI has set ambitious goals for the African vaccine manufacturing industry. The Partnerships for African Vaccine Manufacturing (PAVM), established by the African Union Heads of States and Governments, aims to develop, produce, and supply over 60% of the total vaccine doses required on the continent by 2040. This is a significant increase from the current less than 1% production rate. 𝑾𝒉𝒚 𝒊𝒔 𝒕𝒉𝒆 𝒊𝒏𝒗𝒐𝒍𝒗𝒆𝒎𝒆𝒏𝒕 𝒐𝒇 𝒚𝒐𝒖𝒕𝒉 𝒄𝒓𝒖𝒄𝒊𝒂𝒍 𝒕𝒐 𝒕𝒉𝒆 𝒔𝒖𝒄𝒄𝒆𝒔𝒔 𝒐𝒇 𝒕𝒉𝒊𝒔 𝒊𝒏𝒊𝒕𝒊𝒂𝒕𝒊𝒗𝒆? 🙋♀️ Well, let me share a powerful anecdote with you. During the Ebola outbreak in West Africa, it was the young researchers, scientists, and healthcare professionals who worked tirelessly to develop treatments and find solutions. Youthfulness brings fresh perspectives, innovative ideas, and a relentless drive to make a difference. We, the young generation, are not just the future of tomorrow; we are the voices that need to be heard today! That is why I want to appeal to influential leaders of global health, such as Jean Kaseya, the Director of Africa CDC and the pioneer of this initiative, and Dr Ebere Okereke, the CEO of the Africa Public Health Foundation, to prioritize the involvement of youth (15-35) as defined by the UN in this incredible initiative. Our skills, passions, and enthusiasm can truly propel the African vaccine manufacturing industry forward and ensure a brighter and healthier future for our continent. Aspiring to have a career in vaccinology as I wish? This is your chance to shine! 🌟 By getting involved in AVMI, you can contribute to groundbreaking research, manufacturing processes, and distribution strategies. The AVMA will be a catalyst for such opportunities, and it is up to us to seize them. Embrace the challenge, engage in dialogue, and actively participate in shaping the future of African vaccine manufacturing. Remember, the power to bring about change lies in our hands. Happy 7th Birthday Africa CDC #AVMI2030 #YouthInScience #HealthSecurity #AfricaCDC #AfricanUnion #GlobalHealthLeaders